Pharmaceutical Association of Malaysia
Persatuan Farmaseutikal Malaysia

CODE OF CONDUCT
FOR
NON PRESCRIPTION (OTC) PRODUCTS

75-3, Plaza Damansara, Jalan Medan Setia 1,
Bukit Damansara, 50490 Kuala Lumpur.
Tel: 02-20963493 / 03-20962494 Fax: 03-20952143
E-mail Address: phama@phama.org.my
Website: www.phama.org.my
1. INTRODUCTION

Self medication has been the first line of defence in health care since the origin of man.

Self medication when used properly, plays an important role in the country’s total health picture. Through the use of nonprescription, over the counter (OTC) medicines, appropriate self medication provides relief of symptoms and treatment of ailments and injury without medical supervision.

*Advertising of nonprescription medicines helps raise consumer awareness on health matters and motivate the people to seek out more information about either a medicine or their own health condition. Nonprescription medicines advertising may thereby assist in supporting the proper contribution of self-medication to a country’s healthcare system. Consumers directed advertising empower consumers and enable them to make informed choices on the availability of products for conditions suitable for self-medication.*

It is the responsibility of the pharmaceutical industry to manufacture and market OTC pharmaceutical products that are safe, effective, of good quality, reasonably priced, truthfully advertised and labelled to help consumer understanding.

The members of PhAMA and *ipso facto* the pharmaceutical industry have a dual responsibility. They have a business responsibility to provide good quality, safe and effective OTC medicines and also a social responsibility to advertise truthfully and promote their products to the consumer.

This Code of OTC Pharmaceutical Marketing Practice has been drawn up specifically to meet the Industry’s business and social responsibilities. PhAMA already has a Code of Conduct for ethical products.

The determination of PhAMA and the pharmaceutical industry’s desire for high standards are expressed in these codes on a voluntary basis.

This Code will also apply to health supplements but excludes traditional medicines, cosmetics and medical devices.

2. DEFINITION

OTC Pharmaceutical Products

Any medicinal product which is used in self medication to treat ailments, not requiring a doctor’s prescription.
3. OBJECTIVES

PhAMA, recognising its responsibility to the public, wishes to achieve the following objectives through this voluntary and self-regulating Code of OTC Pharmaceutical Practice.

3.1 Ensure good quality, safe and effective OTC medicine for treatment of minor ailments are made available to the consumer.

3.2 Ensure that members recognise their responsibility to the consumer, the manufacturer and the trade.

3.3 Contribute expertise and co-operate with Government and non-governmental organisations, both national and international, with similar objectives.

3.4 Promote and support a steady and orderly development of OTC medicines.

3.5 Educate the consumer in the proper use of OTC products and responsible self medication.

3.6 Invite non-members to participate and accept the Code.

3.7 Co-ordinate the efforts of its members towards the realisation of these objectives.

4. GENERAL PROVISIONS APPLICABLE TO ALL MARKETING ACTIVITIES

4.1 These provisions apply to pharmaceutical products which are legally available over the counter to the public. Notwithstanding any provisions made under the Code, all marketing activities under the Code must conform to all existing government legislation governing the practice of the pharmaceutical industry.

4.2 The Code is to be applied in the spirit as well as in the letter. That an advertisement is capable of an interpretation which satisfies the Code is not an adequate criterion for its approval; the advertisement must be such that no interpretation which it might reasonably bear would contravene the Code’s requirements. Consideration must be given not only to the impression created by a careful study of an advertisement, but also to the impression likely to be gained from a brief or partial exposure.

4.3 Methods of marketing must never be such as to incite unfavourable comments and bring discredit upon the pharmaceutical industry.

4.3 No marketing activities shall encourage directly or indirectly indiscriminate, unnecessary or excessive use of any medicine. Advertisements implying long usage of a product are only acceptable when such use is justified.

4.4 Consumers of OTC Pharmaceutical should be urged to read and follow the instructions contained in labels, cartons or package inserts.
4.5 Disparaging references to other products of manufacturers should be avoided by
design or implication.

5 ADVERTISING

General Principles

5.1 Advertisements shall be factually true and shall not mislead. No advertisement
shall contain any exaggerated claim, direct or implied.

5.2 No advertisement shall bring disrepute upon the OTC pharmaceutical industry,
undermine confidence in advertising, or prejudice public confidence in medicines.

5.3 Advertisements shall be in terms readily comprehensible to the layman.

5.4 No advertisement shall discourage the consumer from seeking professional
advice.

5.5 No advertisement shall in words or illustration, claim or imply cure of any ailment
or disease.

5.6 No advertisement shall contain any offer to diagnose, prescribe or treat
personally by correspondence.

5.7 All advertisements should be in good taste and not intimidating so as to increase
and/or induce usage.

5.8 No member of the Association shall use ‘subliminal advertising’ i.e. the deliberate
use of visual or aural messages designed to influence people in ways of which
they are not consciously aware.

5.9 An OTC pharmaceutical should not be advertised in a manner which is likely to
lead to its use by young children without parental supervision. Such
advertisements should not be specifically directed towards young children.

Claims & Comparisons

5.10 All descriptions, claims and comparisons which relate to matters of ascertainable
fact shall be capable of appropriate substantiation.

5.11 Exaggerated claims should not be made and all-embracing claims and
superlatives are to be avoided. The word ‘safe’ must not be used without
qualification and claims must not state categorically that a product has no side
effects, toxic hazards or risk of addiction.
5.12 References to speed of absorption, dissolution, distribution and other preliminary activity are acceptable when supported by appropriate evidence. Such evidence may not necessarily be acceptable in support of claims for enhanced speed of relief.

5.13 All comparisons shall be balanced and fair. No comparative statement may, on any reasonably interpretation, mislead consumers about the product being advertised or about any other product with which it might be compared.

**Misleading Advertising**

5.14 Advertisements shall not mislead about the novelty of a preparation. Unless the product has special attributes the description ‘new’ is generally only acceptable for a reasonable time in association with the brand to distinguish the product from other products in the market.

5.15 No advertisement shall by statement or implication suggest that a product contains some unknown active ingredients.

5.16 A product shall not be described as unique or special unless it is significantly different from others on the market. The advertisement as a whole should clearly, indicate the quality of the product which is unique.

5.17 Although it is acceptable to indicate that a product is palatable, medicinal products shall not be presented in a way which could lead to misuse or misunderstanding as to the medicinal nature of the product.

**Professional Endorsement**

5.18 Advertisements shall not refer to any health institution or similar establishments unless there exists a bona fide establishment corresponding to the description used.

5.19 No advertisement shall suggest that a particular product is recommended by a member of the medical, dental, pharmaceutical or related professions. Doctors, dentists, veterinary surgeons, pharmacists, nurses, midwives, etc., should not be depicted in any illustration in such a way as to suggest professional advice or recommendation.

5.20 Claims that a particular product is medically recommended or preferred are unacceptable. Any claim that a particular type of treatment or ingredient is medically recommended or preferred shall be capable of substantiation.

5.21 Implications that a particular group or scientists supports a claim shall be avoided unless the claims are valid and capable of substantiation.

**Prizes & Inducements**

5.22 No member shall promote to the general public, or be associated in any prize competition which is likely to stimulate unnecessarily the use of OTC Pharmaceuticals.
5.23 No member shall promote, or be in any way associated with any schemes which are intended to encourage the sales of OTC Pharmaceuticals if they are likely to introduce any hazard to the general public or to lower the integrity of the industry.

5.24 Medicines shall not be promoted on the basis of an offer to refund money to dissatisfied users.

**Distribution of Samples**

5.22 No member of the Association shall distribute indiscriminately unsolicited samples of OTC Pharmaceuticals.

**6 USE OF PROPRIETARY NAMES**

6.1 Brand names of products of other companies must not be used unless prior consent of the proprietors has been received.

**7 REPRESENTATIVES & PROMOTERS**

**Trade Representatives**

7.1 Representatives should be thoroughly trained and be competent to provide the necessary product information.

7.2 All representative should carry out their work professionally in compliance with this Code.

**Sales promoters**

7.3 Sales promoters should provide service by answering only “simple” queries that deal with maintenance of general food health e.g., dosage, indication, information on what food to take or avoid, etc. Complex queries that deal with issues of pathophysiology and pharmacology should be referred to the pharmacist on duty.

7.4 Tags that allude to their expertise, e.g. Product Consultants, Advisers, etc. should not be allowed to be worn by promoters.

**8 ADMINISTRATION**

8.1 This Code would be periodically reviewed to reflect the highest standard of conduct within the Association.

8.2 Complaints against any member contravening the Code should be in writing addressed to PhAMA’s Ethics Committee.
8.3 Procedures for the lodgment and adjudication of complaints, and penalties to be imposed for breaches of the Code would be adopted from the provisions under the Code of Pharmaceutical Marketing Practices for Prescription (Ethical) Products.

End/-